love the positivity. respectfully, disagree. Even
Post# of 30029
(Total Views: 350)
Posted On: 03/08/2018 12:53:04 PM
.jpg)
love the positivity. respectfully, disagree. Even though the EU study ended in 2016, I interpret this differently, as in, we stopped recruitment and no progress was made in either in Sep 2015, and we permanently concluded the European half in 2016. As in, we intend to do this on the US side only (even though I know we still have euro patents and prep)
Second, we're not going to do a phase III. its phase III enabling. I don't understand the word play other than to clarify beyond saying this is a phase 2b that the next step after the 2b, despite the delays, is a phase 3.
An IND for Eltoprazine was opened with the neurology division of the US FDA in May 2015 that allowed the Company to initiate a multi-center, randomized, placebo-controlled crossover design Phase 2b trial of Eltoprazine in the treatment of PD-LID in the United States and Europe that was put on recruitment hold in September 2015. The European portion of the trial was closed in 2016. The Company is currently preparing to redesign its Phase 2b PD-LID trial into a Phase 3-enabling parallel design clinical trial as a result of the recent approval of Gocovri from Adamas Pharmaceuticals for the treatment of PD-LID. Elto Pharma is in the process of recruiting seasoned management to lead Elto Pharma going forward.
Read More: https://investorshangout.com/post/view?id=496...z59BGawi4D
Second, we're not going to do a phase III. its phase III enabling. I don't understand the word play other than to clarify beyond saying this is a phase 2b that the next step after the 2b, despite the delays, is a phase 3.
An IND for Eltoprazine was opened with the neurology division of the US FDA in May 2015 that allowed the Company to initiate a multi-center, randomized, placebo-controlled crossover design Phase 2b trial of Eltoprazine in the treatment of PD-LID in the United States and Europe that was put on recruitment hold in September 2015. The European portion of the trial was closed in 2016. The Company is currently preparing to redesign its Phase 2b PD-LID trial into a Phase 3-enabling parallel design clinical trial as a result of the recent approval of Gocovri from Adamas Pharmaceuticals for the treatment of PD-LID. Elto Pharma is in the process of recruiting seasoned management to lead Elto Pharma going forward.
Read More: https://investorshangout.com/post/view?id=496...z59BGawi4D
(2)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼